“Enoyl-ACP reductase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Enoyl-ACP reductase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered • Global coverage
Enoyl-ACP reductase inhibitors Understanding
Enoyl-ACP reductase inhibitors: Overview Enoyl-acyl carrier protein (ACP) reductases (ENRs) catalyze the last step of the elongation cycle in the synthesis of fatty acids. Fatty acid biosynthesis is essential for survival in mammals, plants, fungi and bacteria (the archaea make isoprenoid-based lipids). ENR displays an unusual diversity among organisms. The growing interest in ENRs is mainly due to the fact that a variety of both synthetic and natural antibacterial compounds are shown to specifically target their activity. In mammals, there is no homologue to ENR, which makes it an optimal candidate target for selective anti-infective drugs.
Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence Enoyl-ACP reductase inhibitors R&D. The therapies under development are focused on novel approaches for Enoyl-ACP reductase inhibitors.
Enoyl-ACP reductase inhibitors Emerging Drugs Chapters This segment of the Enoyl-ACP reductase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Enoyl-ACP reductase inhibitors Emerging Drugs • Afabicin (Debio 1450): Debiopharm
Afabicin (Debio 1450), is the first-in class of a novel antibiotic class, fabiotics, that inhibits fatty acid synthesis in staphylococci by targeting the Fabl enzyme. It fulfills all four WHO 2020 innovativeness criteria, i.e. new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes. As a result of its potent selective activity, afabicin specifically targets staphylococci while preserving intestinal microbiota. The compound currently is in phase II research for the treatment of Bone and Joint infections (BJI) due to staphylococci. The compound is also being researched in staphylococcal acute bacterial skin and skin structure infections (ABSSSI).
Further product details are provided in the report……..
Enoyl-ACP reductase inhibitors: Therapeutic Assessment This segment of the report provides insights about the different Enoyl-ACP reductase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players working on Enoyl-ACP reductase inhibitors
There are approx. 2+ key companies which are developing the Enoyl-ACP reductase inhibitors. The companies which have their Enoyl-ACP reductase inhibitors drug candidates in the most advanced stage, i.e. Phase II include, Debiopharm.
This report covers around 3+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Enoyl-ACP reductase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Enoyl-ACP reductase inhibitors: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Enoyl-ACP reductase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Enoyl-ACP reductase inhibitors drugs.
Current Scenario and Emerging Therapies: • How many companies are developing Enoyl-ACP reductase inhibitors drugs?
• How many Enoyl-ACP reductase inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Enoyl-ACP reductase inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Enoyl-ACP reductase inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Enoyl-ACP reductase inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?
Bronchopulmonary Dysplasia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Bronchopulmonary Dysplasia - Drugs In Development, 2022, provides an overview of the Bronchopulmonary Dysplasia...
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 22.214.171.124) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Tyrosine Protein Kinase...
120 pages •
By Infiniti Research Limited
• Apr 2022
Global Neurodegenerative Diseases Therapeutics Market 2022-2026 The analyst has been monitoring the neurodegenerative diseases therapeutics market and it is poised to grow by $ 19.74 bn during 2022-2026, accelerating at a CAGR of 7.98% during the forecast period. Our report on the neurodegenerative diseases therapeutics...
The global rotator cuff injury treatment market is projected to reach USD 1,244 million by 2026 from USD 989 million in 2021, at a CAGR of 4.7% during the forecast period”. The key factors fueling the growth of this market include an increase in sports related shoulder injuries, technological advancements in arthroscopic surgical devices,...
Genital Herpes Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Drugs In Development, 2022, provides an overview of the Genital Herpes (Infectious Disease) pipeline...
Sarcopenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an...
Gonorrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an...
Burns Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Burns - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview...
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 126.96.36.199) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Protein Kinase C Theta Type - Drugs In Development, 2022’; Protein Kinase...
Prescription Drug Sales
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.